(Reuters) – The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for advanced form of breast cancer.
The logo of U.S. pharmaceutical corporation Pfizer Inc. is seen at a branch in Zurich, Switzerland October 2, 2018. REUTERS/Arnd Wiegmann
The FDA also approved Myriad Genetics’ diagnostic test to identify breast cancer patients who are eligible for Pfizer’s drug, talazoparib.
Reporting by Manogna Maddipatla in Bengaluru; Editing by Maju Samuel